ReviewInternational journal of nanomedicine2026
Aptamers in Osteoimmune Regulation: Scientific Rationale, Emerging Evidence and Translational Challenges.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoimmune disorders are difficult to treat because pathogenic signals are spatially restricted, temporally dynamic, and distributed across immune, skeletal, vascular, and microbial compartments. Aptamers provide a programmable recognition platform that may address these limitations, although their application in osteoimmune systems remains largely exploratory. This critical narrative review defines the scientific rationale for aptamer-based osteoimmune regulation, maps the current state of aptamer research across biological axes closely associated with osteoimmune regulation, and highlights potential targets for future therapeutic intervention. Aptamer contributions are classified into three distinct functional modes: direct molecular regulation, targeted navigation and niche reconditioning. We further analyze challenges imposed by acidic, nuclease-rich, and oxidizing skeletal environments, modification-dependent pharmacokinetics, and innate nucleic-acid sensing. Current evidence remains dominated by indirect and multicomponent systems, whereas direct aptamer-mediated osteoimmune pharmacology is supported by a comparatively limited number of studies. Future studies must establish aptamer-specific target engagement, causal immune-to-bone mechanisms, disease-relevant stability, and functional skeletal outcomes before clinical translation can be credibly pursued.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.